South America Tulathromycin Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Swine) and By Country (Brazil, Argentina, Colombia, Rest of South America) Forecasts, 2026-2034

Last Updated: September 01, 2026 | Author: Dhanashri Chandgude | Format:

South America Tulathromycin Market Size

The South America tulathromycin market size was valued at USD 78 million in 2025 and is projected to grow from USD 84.86 million in 2026 to reach USD 166.63 million by 2034, growing at a CAGR of 8.8% during the forecast period 2026–2034.

An antibiotic called tulathromycin treats respiratory diseases in dairy cattle and swine. Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin.

The high prevalence of BRD and SRD drives the South American tulathromycin market. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin is an opportunity for the tulathromycin market.

Download a Free Sample To learn more about this report.

Animal Type Insights

The market is segmented into cattle and swine. Cattle dominates the market and is expected to register a CAGR of 3.7% over the forecast period.Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.

South America Tulathromycin Market Size By Segments

Request Customizationto receive a tailored report.

South America Tulathromycin Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The South American tulathromycin market is segmented based on the country into Brazil. Brazil dominates the country market and is expected to grow at a CAGR of 3.6% during the forecast period.

The main economies in South America with the highest populations of cattle and pigs are Brazil, Mexico, Argentina, and Colombia. According to our research, Brazil is home to more than 51% of the world's cattle. Additionally, the region is home to more than 29% of the world's cattle, contributing to 29% of global beef production. Brazil has seen a sharp rise in the total number of cattle in recent years as the nation has begun to export more beef. However, compared to North America, South America has a far lower prevalence of BRD.

As of 2020, South America has over 4 million pigs. The number keeps increasing as more people in the area start eating pork. For treating SRD, tulathromycin is anticipated to have higher growth prospects as the number of pigs in the area rises. In some of the largest pork-producing countries in South America, the prevalence of SRD is notably high.

List of Key and Emerging Players in South America Tulathromycin Market

Zoetis

Zhejiang Genebest Pharmaceutical

Wisdom Pharmaceutical

Amicogen Biopharm

Hubei Honch Pharmaceutical

Livzon New North River Pharmaceutical

AVF Chemical Industrial

Jiangsu Lingyun Pharmaceutical

Key Industry Developments

May 2026

Zoetis expanded the availability of Draxxin KP (tulathromycin and ketoprofen injection) across Latin American markets, strengthening its livestock respiratory disease treatment portfolio and supporting cattle producers with dual-action therapy.

February 2026

MSD Animal Health expanded its veterinary pharmaceutical distribution network across South America through new regional distribution agreements, improving access to tulathromycin-based respiratory disease treatments for livestock producers.

November 2025

Ourofino Saúde Animal expanded production capacity at its animal health manufacturing facility in Brazil to support increasing regional demand for injectable veterinary antimicrobials, including macrolide antibiotics.

August 2025

Biogénesis Bagó strengthened its commercial partnership network across South America to expand the distribution of livestock health products, including respiratory disease therapeutics for cattle.

May 2025

Ceva Saúde Animal expanded its cattle health portfolio in South America through new veterinary product commercialization initiatives, strengthening regional access to antimicrobial treatments for bovine respiratory diseases.

Report Scope

Segmentation

By Animal Type 2

Cattle
Swine

Competitive Coverage Zoetis · Zhejiang Genebest Pharmaceutical · Wisdom Pharmaceutical · Amicogen Biopharm · Hubei Honch Pharmaceutical

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The market size is growing at a CAGR of 8.8% from 2026 to 2034.

High prevalence of BRD and SRD is the key driver for the growth of this market.

The key players in this market are Zoetis, Zhejiang Genebest Pharmaceutical, Wisdom Pharmaceutical, Amicogen Biopharm, Hubei Honch Pharmaceutical, Livzon New North River Pharmaceutical, AVF Chemical Industrial, Jiangsu Lingyun Pharmaceutical.

The key restraint in the market is Entry of generic tulathromycin.

About the Author

Dhanashri Chandgude

Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.